This paper is in the following e-collection/theme issue:

Non-randomized Protocols and Methods (ehealth) (564) Wearable Devices and Sensors (876) Substance Abuse (410) Opioid and Related Substance Misuse (142) Formative Evaluation of Digital Health Interventions (2353) Adverse Drug Events Detection, Pharmacovigilance and Surveillance (152) Harm Reduction Approaches (9)

Published on in Vol 13 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/57367, first published .
Overdose Detection Among High-Risk Opioid Users Via a Wearable Chest Sensor in a Supervised Injecting Facility: Protocol for an Observational Study

Overdose Detection Among High-Risk Opioid Users Via a Wearable Chest Sensor in a Supervised Injecting Facility: Protocol for an Observational Study

Overdose Detection Among High-Risk Opioid Users Via a Wearable Chest Sensor in a Supervised Injecting Facility: Protocol for an Observational Study

Authors of this article:

Basak Tas1 Author Orcid Image ;   Will Lawn2 Author Orcid Image ;   Marianne Jauncey3 Author Orcid Image ;   Mark Bartlett3 Author Orcid Image ;   Paul Dietze4 Author Orcid Image ;   Daniel O'Keefe4 Author Orcid Image ;   Nico Clark5 Author Orcid Image ;   Bruce Henderson6 Author Orcid Image ;   Catriona Cowan6 Author Orcid Image ;   Osian Meredith6 Author Orcid Image ;   John Strang1, 7 Author Orcid Image
Article Authors Cited by Tweetations (1) Metrics

Basak Tas   1 , PhD ;   Will Lawn   2 , BA, PhD ;   Marianne Jauncey   3 , BMed, MPH ;   Mark Bartlett   3 , BSc, DipEd, RN, MPH, Grad Dip App Epi ;   Paul Dietze   4 , PhD ;   Daniel O'Keefe   4 , MPH, PhD ;   Nico Clark   5 , MBBS, MPH, MD ;   Bruce Henderson   6 , MBChB ;   Catriona Cowan   6 , BSc ;   Osian Meredith   6 , BSc, MPhil, PhD ;   John Strang   1, 7 , MBBS, MD

1 National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom

2 Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom

3 Medically Supervised Injecting Centre, Sydney, Australia

4 Disease Elimination, Burnet Institute, Melbourne, Australia

5 Royal Melbourne Hospital, Melbourne, Australia

6 PneumoWave LTD, Motherwell, United Kingdom

7 South London and Maudsley NHS Foundation Trust, London, United Kingdom

Corresponding Author:

  • John Strang, MBBS, MD
  • National Addiction Centre
  • Institute of Psychiatry, Psychology and Neuroscience
  • King's College London
  • Addiction Sciences Building
  • London, SE5 8BB
  • United Kingdom
  • Phone: 44 2078480438
  • Email: john.strang@kcl.ac.uk